Aziyo Biologics, Inc. Class A (ELUT) has disclosed a new risk, in the Innovation / R&D category.
Aziyo Biologics, Inc. Class A faces heightened business risk following the divestiture of its Orthobiologics Business, which significantly contributed to prior revenues. The company’s future now hinges on the performance of a smaller portfolio and the success of CanGarooRM, a novel product pending FDA approval. With no guarantees of increased sales or profitability from its existing businesses, the uncertainty surrounding CanGarooRM’s regulatory outcome poses a material risk to Aziyo’s fiscal health and growth trajectory. Any delay or failure in CanGarooRM’s market introduction could materially and adversely impact the company’s operations and financial stability.
Overall, Wall Street has a Moderate Buy consensus rating on ELUT stock based on 1 Buy.
To learn more about Aziyo Biologics, Inc. Class A’s risk factors, click here.
